1073431--2/26/2010--Life_Technologies_Corp

related topics
{property, intellectual, protect}
{debt, indebtedness, cash}
{product, market, service}
{regulation, government, change}
{acquisition, growth, future}
{operation, international, foreign}
{cost, regulation, environmental}
{product, candidate, development}
{customer, product, revenue}
{system, service, information}
{personnel, key, retain}
{product, liability, claim}
{condition, economic, financial}
{cost, operation, labor}
{regulation, change, law}
{competitive, industry, competition}
Risks Related to the Growth of Our Business The Company must continually offer new products and services The Company must be able to manufacture new and improved products to meet customer demand on a timely and cost-effective basis The Company may not successfully integrate the Applied Biosystems business or realize all of the anticipated benefits of our merger with Applied Biosystems The Company s future growth depends in part on our ability to acquire new products, services, and technologies through additional acquisitions, which may absorb significant resources and may not be successful The Company may not successfully manage its current and future divestitures, and as a result, may not achieve some or all of the expected benefits of such divestitures The Company faces significant competition Consolidation trends in both our market and that of our customers have increased competition Adverse conditions in the global economy and disruption of financial markets may significantly harm our revenue, profitability and results of operations A significant portion of our sales are dependent upon our customers capital spending policies and research and development budgets, and government funding of research and development programs at universities and other organizations, which are subject to significant and unexpected decreases Some of our customers are requiring us to change our sales arrangements to lower their costs which may limit our pricing flexibility and harm our business Risks Related to the Development and Manufacturing of Our Products Our business depends on our ability to license new technologies from others Our business could be harmed if we lose rights to technologies that we have licensed from others Violation of government regulations or voluntary quality programs could harm demand for our products or services The Company relies on other companies for the manufacture of some of our products and also for the supply of some components of the products we manufacture on our own which may hinder our ability to satisfy customer demand Risks Related to Our Operations Loss of key personnel may adversely affect our business We have substantial indebtedness, which could adversely affect our cash flows, business and financial condition Our credit facilities contain restrictions that limit our flexibility in operating our business The Company could incur more indebtedness, which may increase the risks associated with our substantial leverage, including our ability to service our indebtedness and pay dividends on our common stock The Company could lose the tax deduction for interest expense associated with our convertible senior notes due in 2023, the convertible senior notes due in 2024 and the convertible senior notes due in 2025 Our federal, state and local income tax returns may, from time to time, be selected for audit by the taxing authorities, which may result in tax assessments or penalties The Company s business, particularly the development and marketing of information-based products and services, depends on the continuous, effective, reliable, and secure operation of our computer hardware, software, and Internet applications and related tools and functions Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses Risks Related to Our International Operations International unrest or foreign currency fluctuations could cause volatility in our international sales and our financial results. Risks Related to Our Intellectual Property The Company may not be able to effectively and efficiently protect and enforce our proprietary technology The Company is currently, and could in the future be, subject to lawsuits, arbitrations, investigations, and other legal actions with private parties and governmental entities, particularly involving claims for infringement of patents and other intellectual property rights, and we may need to obtain licenses to intellectual property from others Disclosure of trade secrets could cause harm to our business Some of the intellectual property that is important to our business is owned by other companies or institutions and licensed to us, and legal actions against them could harm our business Risks Related to Environmental and Product Liability Issues Risks related to handling of hazardous materials and other regulations governing environmental safety Potential product liability claims could cause harm to our business

Full 10-K form ▸

related documents
1073431--3/2/2009--Life_Technologies_Corp
1073431--3/1/2006--INVITROGEN_CORP
1107216--3/12/2008--ORCHID_CELLMARK_INC
1107216--3/15/2007--ORCHID_CELLMARK_INC
1342126--3/17/2008--Morgans_Hotel_Group_Co.
1342126--3/16/2009--Morgans_Hotel_Group_Co.
1145460--3/1/2007--INVERNESS_MEDICAL_INNOVATIONS_INC
1145460--3/16/2006--INVERNESS_MEDICAL_INNOVATIONS_INC
1107216--5/24/2006--ORCHID_CELLMARK_INC
1261694--3/16/2006--TESSERA_TECHNOLOGIES_INC
924717--12/11/2009--SURMODICS_INC
1107216--3/16/2009--ORCHID_CELLMARK_INC
924717--12/15/2008--SURMODICS_INC
924717--12/14/2010--SURMODICS_INC
1087294--3/19/2010--CUMBERLAND_PHARMACEUTICALS_INC
1342126--3/31/2006--Morgans_Hotel_Group_Co.
1145460--3/2/2009--INVERNESS_MEDICAL_INNOVATIONS_INC
1342126--3/30/2007--Morgans_Hotel_Group_Co.
1145460--2/29/2008--INVERNESS_MEDICAL_INNOVATIONS_INC
706539--3/16/2006--CHIRON_CORP
917273--2/26/2009--RAMBUS_INC
1145460--3/1/2010--INVERNESS_MEDICAL_INNOVATIONS_INC
945828--9/28/2010--AMERITYRE_CORP
924642--4/1/2010--DIGITAL_ANGEL_CORP
1318310--3/13/2008--ev3_Inc.
1274563--4/15/2010--HELICOS_BIOSCIENCES_CORP
865917--1/29/2010--VERSANT_CORP
868368--12/10/2010--ROCHESTER_MEDICAL_CORPORATION
720762--10/29/2010--NON_INVASIVE_MONITORING_SYSTEMS_INC_/FL/
1052595--3/11/2010--Red_Lion_Hotels_CORP